Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05409209
Active, not recruiting Observational

Carotid Plaque Length to Predict Cardiovascular Events

NCT05409209 · tracked via the Priya Life Science China tracker
Sponsor
Changhai Hospital
Phase
Observational
Started
2017-01-01
Last updated
2024-09-19

Condition(s) studied

Coronary Artery Disease

Study summary

This multicenter study involved 5 hospitals (Changhai Hospital; Yueyang Hospital of Shanghai University of Traditional Chinese Medicine; Gongli Hospital; Putuo Hospital of Shanghai University of Traditional Chinese Medicine; No. 904 Hospital of the PLA Joint Logistics Support Force Wuxi). The study enrolled 3000 patients for suspected CAD who referred to coronary angiography from January 2017 through December 2018.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients≥18 years old, those who underwent carotid ultrasonography and first coronary angiography simultaneously. Exclusion Criteria: * Patients with known coronary artery disease, previous coronary or carotid revascularization, missing carotid ultrasound or coronary angiography results.

Primary outcome measure(s)

  • major cardiovascular event — 3 years
    A composite of cardiovascular death, myocardial infarction, and ischemic stroke

Trial sites (5)

FacilityCityRegionStatus
No. 904 Hospital of the PLA Joint Logistics Support Force Wuxi Jiangsu
Changhai Hospital Shanghai Shanghai Municipality
Gongli Hospital Shanghai Shanghai Municipality
Putuo Hospital Shanghai Shanghai Municipality
Yueyang Hospital Shanghai Shanghai Municipality

More Changhai Hospital trials in China

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer Recruiting
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD Recruiting
Association Between Carotid Plaque Length and Cardiovascular Outcomes Active, not recruiting
AI-Powered Precision Decision-Making for Pancreatic Diseases Recruiting
Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT) Recruiting

Other trials for the same condition

Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG Starting soon
INSIGHTFUL-FFR Clinical Trial Recruiting
Identifying Vulnerable CoronAry PLaqUes With Artificial IntElligence-assisted CT Angiography Enrolling by invitation
Association Between Carotid Plaque Length and Cardiovascular Outcomes Active, not recruiting
IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05409209 on ClinicalTrials.gov ↗ ← All trials in China